At TDI, we aim to bring powerful drug discovery technologies to researchers across the Tri-Institutional community. We have established productive partnerships with a range of cutting-edge technology-based organizations, including Ablexis, Charles River Labs, ChemPartner, Frontage, Horizon, LakePharma, NY Structural Biology, Schrödinger, Taconic, WuXi AppTec and XTAL, among others. We continue to develop strategic relationships with world-class providers of tools and technologies in both the small molecule and antibody realms.

Takeda Pharmaceuticals

Key to TDI's success is our unique relationship with Takeda Pharmaceutica Co.. Takeda is an incredibly valuable partner for TDI and their investment in the TDI vision allowed us to establish TDI’s pharmaceutical quality, small molecule and biologics drug discovery teams.

As part of our partnership, senior scientific leaders from Takeda participate in TDI’s Scientific Advisory Board meetings, helping us advance innovative translational research programs. While TDI is a lab-based research organization, Takeda’s support also enables TDI’s access of a wide variety of complex, highly valuable technologies required by our small molecule and biologics scientists to rapidly advance translational research projects. These additional resources empower TDI to advance projects quickly and efficiently.